InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) CEO Eric Adams recently sat down for two separate interviews regarding InMed's proprietary biosynthesis process, their patent filings and their research on using cannabinoids to treat various diseases.
TheSeedInvestor
Read our Medical Marijuana Compound Report for Free Today!
There will be a sudden wave of "Marijuana Millionaires" in 2017 - will you be one?

 
13x13x1 READ MORE
Emerging Market Report
 
LEARN MORE
Dear Seed Investor, 

InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) CEO Eric Adams recently sat down for two separate interviews regarding InMed's proprietary biosynthesis process, their patent filings and their research on using cannabinoids to treat various diseases.

InMed is one of the most exciting companies that we have come across, and both interviews are MUST LISTENS to get a good understanding on the company and their groundbreaking research.  

From the Midas Letter: 

InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) (FRA:MWG2) performs research on extracted and purified cannabinoids to treat severe disease. President and CEO Eric Adams talks to James about the Canadian cannabinoid market, patenting, and their research on oils to treat a rare skin disorder often first seen on children.

LISTEN TO PODCAST AND READ THE TRANSCRIPT AT THE MIDAS LETTER

In addition to that interview, Mr. Adams also sat down with The Wall Street Analyzer for another in-depth interview: 

LISTEN TO THE INTERVIEW AT THE WALL STREET ANALYZER

We highly recommend having a listen over the weekend. 

High Profits, 

The Seed Investor
 
Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimerDisclaimer.

This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor. 
 
32x32x1   32x32x2   32x32x3
TheSeedInvestor.com
9375 E Shea Blvd Ste 100
Scottsdale 85260
info@theseedinvestor.com
 
©2018, All Rights Reserved  |  Unsubscribe   |   View this in Browser

To keep receiving emails from us, please add us to your address book.